Skip to main content
Back
Watch Compare

Calidi Biotherapeutics, Inc.

Data quality: 83%
Also listed as CLDWW NYSE
CLDI
NYSE Manufacturing Chemicals
$0.26
▲ $0.01 (4.11%)
Mkt Cap: 2.82 M
Price
$0.26
Mkt Cap
2.82 M
Day Range
$0.25 — $0.27
52-Week Range
$0.21 — $19.20
Volume
757,584
Open $0.26
50D / 200D Avg
$0.62
58.47% below
50D / 200D Avg
$2.18
88.17% below

Quick Summary

Key Takeaways

Debt/Equity of 0.09 — conservative balance sheet
Negative free cash flow of -21.29 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-458.56%
Below sector avg (-53.41%)
ROIC-249.18%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.09
Below sector avg (0.31)
Current Ratio2.12
Interest Coverage-202.40

Valuation

PE (TTM)
-0.14
Above sector avg (-1.48)
P/B Ratio0.41
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.1 -1.5
P/B 0.4 1.6
ROE % -458.6 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E 0.1 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -19.91 M
ROE -458.56% ROA -170.28%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -21.29 M
ROIC -249.18% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.09 Current Ratio 2.12
Interest Coverage -202.40 Asset Turnover N/A
Working Capital 5.84 M Tangible Book Value 6.92 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.14 Forward P/E N/A
P/B Ratio 0.41 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -756.00%
Market Cap 2.82 M Enterprise Value 3.42 M
Per Share
EPS (Diluted TTM) -5.95 Revenue / Share N/A
FCF / Share -1.95 OCF / Share -1.95
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 106.97%
SBC-Adj. FCF -23.64 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Revenue — — 45,000.0 — —
Net Income -19.91 M -22.14 M -29.22 M 3.39 M 3.53 M
EPS (Diluted) -5.95 -2.97 1.73 — —
Gross Profit — — — — —
Operating Income -20.24 M -21.78 M -28.99 M -1.78 M -4.67 M
EBITDA — — — — —
R&D Expenses 9.74 M 8.88 M 13.01 M — —
SG&A Expenses 10.50 M 12.90 M 15.98 M — —
D&A 1.65 M — — — —
Interest Expense 100,000.0 700,000.0 1.10 M — —
Income Tax 15,000.0 14,000.0 16,000.0 — 346,987.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Total Assets 8.86 M 14.18 M 10.02 M 231.77 M 42.85 M
Total Liabilities 5.10 M 12.21 M 18.25 M 16.45 M 5.61 M
Shareholders' Equity 3.76 M 1.53 M -8.24 M -14.69 M -5.21 M
Total Debt 600,000.0 600,000.0 2.06 M — —
Cash & Equivalents — 9.60 M — 1.06 M —
Current Assets 6.26 M 10.23 M 4.30 M 1.48 M 401,671.0
Current Liabilities 3.94 M 9.50 M 10.23 M 410,985.0 4.54 M